

***Amendments to the Claims***

This listing of claims replaces all previous versions and listings of claims.

**Listing of Claims:**

1-24. (canceled)

25. (previously presented) An isolated antibody or fragment thereof that specifically binds to a protein selected from the group consisting of:

- (a) amino acid residues +1 to 371 of SEQ ID NO:2;
- (b) amino acid residues +23 to +371 of SEQ ID NO:2;
- (c) amino acid residues +1 to +231 of SEQ ID NO:2;
- (d) amino acid residues +23 to +225 of SEQ ID NO:2;

(e) a protein consisting of a portion of SEQ ID NO:2, wherein said portion comprises at least 30 contiguous amino acid residues of SEQ ID NO:2; and

(f) a protein consisting of a portion of SEQ ID NO:2, wherein said portion comprises at least 50 contiguous amino acid residues of SEQ ID NO:2.

26. (previously presented) The antibody or fragment thereof of claim 25 that specifically binds protein (a).

27. (previously presented) The antibody or fragment thereof of claim 25 that specifically binds protein (b).

28. (previously presented) The antibody or fragment thereof of claim 25 that specifically binds protein (c).

29. (previously presented) The antibody or fragment thereof of claim 25 that specifically binds protein (d).

19  
30. (previously presented) The antibody or fragment thereof of claim 25 that specifically binds protein (e).

20  
31. (previously presented) The antibody or fragment thereof of claim 25 that specifically binds protein (f).

21  
32. (previously presented) The antibody or fragment thereof of claim 26 that specifically binds protein (b).

22  
33. (previously presented) The antibody or fragment thereof of claim 27 wherein said protein bound by said antibody or fragment thereof is glycosylated.

23  
34. (previously presented) The antibody or fragment thereof of claim 27, which is a human antibody.

24  
35. (previously presented) The antibody or fragment thereof of claim 27, which is a polyclonal antibody.

25  
36. (previously presented) The antibody or fragment thereof of claim 27, which is selected from the group consisting of:

- (a) a chimeric antibody;
- (b) a humanized antibody;
- (c) a single chain antibody; and
- (d) a Fab fragment.

26  
37. (previously presented) The antibody or fragment thereof of claim 27 which is labeled.

27  
38. (previously presented) The antibody or fragment thereof of claim 37 wherein the label is selected from the group consisting of:

- (a) an enzyme;
- (b) a fluorescent label;
- (c) a luminescent label;
- (d) a bioluminescent label; and
- (e) a prosthetic group.

11 4  
39. (previously presented) The antibody or fragment thereof of claim 27 wherein said antibody or fragment thereof specifically binds to said protein in a Western blot.

12 4  
40. (previously presented) The antibody or fragment thereof of claim 27 wherein said antibody or fragment thereof specifically binds to said protein in an ELISA.

13 4  
41. (previously presented) An isolated cell that produces the antibody or fragment thereof of claim 27. 4

14 4  
42. (previously presented) A hybridoma that produces the antibody or fragment thereof of claim 27. 4

15 4  
43. (currently amended) A method of detecting CRGGCL cytokine receptor common gamma chain like protein in a biological sample comprising:

- (a) contacting the biological sample with the antibody or fragment thereof of claim 27; and
- (b) detecting the CRGGCL cytokine receptor common gamma chain like protein in the biological sample.

16 4  
44. (previously presented) The method of claim 43 wherein the antibody or fragment thereof is a polyclonal antibody.

*21*  
45. (currently amended) An isolated antibody or fragment thereof obtained from an animal that has been immunized with a protein selected from the group consisting of:

- (a) a protein comprising amino acid residues +1 to 371 of SEQ ID NO:2;
- (b) a protein comprising amino acid residues +23 to +371 of SEQ ID NO:2;
- (c) a protein comprising amino acid residues +1 to +231 of SEQ ID NO:2;
- (d) a protein comprising amino acid residues +23 to +225 of SEQ ID NO:2;
- (e) a protein comprising the amino acid sequence of at least 30 contiguous amino acid residues of SEQ ID NO:2; and
- (f) a protein comprising the amino acid sequence of at least 50 contiguous amino acid residues of SEQ ID NO:2;

wherein said antibody or fragment thereof specifically binds to said amino acid sequencee residues.

*21*  
46. (previously presented) The antibody or fragment thereof of claim *45* obtained from an animal immunized with protein (a).

*21*  
47. (previously presented) The antibody or fragment thereof of claim *45* obtained from an animal immunized with protein (b).

*21*  
48. (previously presented) The antibody or fragment thereof of claim *45* obtained from an animal immunized with protein (c).

*21*  
49. (previously presented) The antibody or fragment thereof of claim *45* obtained from an animal immunized with protein (d).

*21*  
50. (previously presented) The antibody or fragment thereof of claim *45* obtained from an animal immunized with protein (e).

*21*  
51. (previously presented) The antibody or fragment thereof of claim *45* obtained from an animal immunized with protein (f).

28

52. (previously presented) The antibody or fragment thereof of claim 45,  
which is a monoclonal antibody.

29

53. (previously presented) The antibody or fragment thereof of claim 45,  
which is selected from the group consisting of:

- (a) a chimeric antibody;
- (b) a polyclonal antibody;
- (c) a humanized antibody;
- (d) a single chain antibody; and
- (e) a Fab fragment.

30

54. (previously presented) An isolated monoclonal antibody or fragment  
thereof that specifically binds to a protein selected from the group consisting of:

- (a) a protein consisting of amino acid residues +1 to 371 of SEQ ID NO:2;
- (b) a protein consisting of amino acid residues +23 to +371 of SEQ ID NO:2;
- (c) a protein consisting of amino acid residues +1 to +231 of SEQ ID NO:2;
- (d) a protein consisting of amino acid residues +23 to +225 of SEQ ID NO:2;
- (e) a protein consisting of a portion of SEQ ID NO:2, wherein said portion  
comprises at least 30 contiguous amino acid residues of SEQ ID NO:2; and
- (f) a protein consisting of a portion of SEQ ID NO:2, wherein said portion  
comprises at least 50 contiguous amino acid residues of SEQ ID NO:2.

31

55. (previously presented) The antibody or fragment thereof of claim 54 that  
specifically binds protein (a).

32

56. (previously presented) The antibody or fragment thereof of claim 54 that  
specifically binds protein (b).

33

57. (previously presented) The antibody or fragment thereof of claim 54 that  
specifically binds protein (c).

~~44~~ 38. (previously presented) The antibody or fragment thereof of claim ~~54~~ that specifically binds protein (d).

~~45~~ 39. (previously presented) The antibody or fragment thereof of claim ~~54~~ that specifically binds protein (e).

~~46~~ 40. (previously presented) The antibody or fragment thereof of claim ~~54~~ that specifically binds protein (f).

~~33~~ 41. (previously presented) The antibody or fragment thereof of claim ~~56~~ wherein said protein bound by said antibody or fragment thereof is glycosylated.

~~34~~ 42. (previously presented) The antibody or fragment thereof of claim ~~56~~, which is a human antibody.

~~35~~ 43. (previously presented) The antibody or fragment thereof of claim ~~56~~, which is selected from the group consisting of:

- (a) a chimeric antibody;
- (b) a humanized antibody;
- (c) a single chain antibody; and
- (d) a Fab fragment.

~~36~~ 44. (previously presented) The antibody or fragment thereof of claim ~~56~~, which is labeled.

~~37~~ 45. (previously presented) The antibody or fragment thereof of claim ~~64~~ wherein the label is selected from the group consisting of:

- (a) an enzyme;
- (b) a fluorescent label;
- (c) a luminescent label;

- (d) a bioluminescent label; and
- (e) a prosthetic group.

38  
66. (previously presented) The antibody or fragment thereof of claim 56  
wherein said antibody or fragment thereof specifically binds to said protein in a Western blot.

39  
67. (previously presented) The antibody or fragment thereof of claim 56  
wherein said antibody or fragment thereof specifically binds to said protein in an ELISA.

40  
68. (previously presented) An isolated cell that produces the antibody or fragment thereof of claim 56. 32

41  
69. (previously presented) A hybridoma that produces the antibody or fragment thereof of claim 56. 32

42  
70. (currently amended) A method of detecting CRCCGCL cytokine receptor common gamma chain like protein in a biological sample comprising:

- (a) contacting the biological sample with the antibody or fragment thereof of claim 56; and
- (b) detecting the CRCCGCL cytokine receptor common gamma chain like protein in the biological sample.

47  
71. (previously presented) An isolated antibody or fragment thereof that specifically binds to a protein selected from the group consisting of:

- (a) a protein consisting of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit Number 209691 or 209641;
- (b) a protein consisting of the mature form of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209691 or 209641;
- (c) a protein consisting of the extracellular soluble domain of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209691 or 209641;

(d) a protein consisting of a portion of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209691 or 209641, wherein said portion comprises at least 30 contiguous amino acid residues of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209691 or 209641; and

(e) a protein consisting of a portion of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209691 or 209641, wherein said portion comprises at least 50 contiguous amino acid residues of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209691 or 209641.

48  
72. (previously presented) The antibody or fragment thereof of claim 71 that specifically binds protein (a).

50  
73. (previously presented) The antibody or fragment thereof of claim 71 that specifically binds protein (b).

63  
74. (previously presented) The antibody or fragment thereof of claim 71 that specifically binds protein (c).

64  
75. (previously presented) The antibody or fragment thereof of claim 71 that specifically binds protein (d).

15  
76. (previously presented) The antibody or fragment thereof of claim 71 that specifically binds protein (e).

77. (previously presented) The antibody or fragment thereof of claim 72 that specifically binds protein (b).

51  
78. (previously presented) The antibody or fragment thereof of claim 73 wherein said protein bound by said antibody or fragment thereof is glycosylated.

<sup>52</sup>  
79. (previously presented) The antibody or fragment thereof of claim <sup>53</sup> ~~73~~,  
which is a human antibody.

<sup>53</sup>  
80. (previously presented) The antibody or fragment thereof of claim <sup>54</sup> ~~73~~,  
which is a polyclonal antibody.

<sup>54</sup>  
81. (previously presented) The antibody or fragment thereof of claim <sup>55</sup> ~~73~~,  
which is selected from the group consisting of:

- (a) a chimeric antibody;
- (b) a humanized antibody;
- (c) a single chain antibody; and
- (d) a Fab fragment.

<sup>55</sup>  
82. (previously presented) The antibody or fragment thereof of claim <sup>56</sup> ~~73~~,  
which is labeled.

<sup>56</sup>  
83. (previously presented) The antibody or fragment thereof of claim <sup>57</sup> ~~82~~,  
wherein the label is selected from the group consisting of:

- (a) an enzyme;
- (b) a fluorescent label;
- (c) a luminescent label;
- (d) a bioluminescent label; and
- (e) a prosthetic group.

<sup>57</sup>  
84. (previously presented) The antibody or fragment thereof of claim <sup>58</sup> ~~73~~,  
wherein said antibody or fragment thereof specifically binds to said protein in a Western  
blot.

<sup>58</sup>  
85. (previously presented) The antibody or fragment thereof of claim <sup>59</sup> ~~73~~,  
wherein said antibody or fragment thereof specifically binds to said protein in an ELISA.

*59*  
86. (previously presented) An isolated cell that produces the antibody or fragment thereof of claim *73*.<sup>50</sup>

*60*  
87. (previously presented) A hybridoma that produces the antibody or fragment thereof of claim *73*.<sup>50</sup>

*61*  
88. (currently amended) A method of detecting CRCCGCL cytokine receptor common gamma chain like protein in a biological sample comprising:

- (a) contacting the biological sample with the antibody or fragment thereof of claim *73*; and
- (b) detecting the CRCCGCL cytokine receptor common gamma chain like protein in the biological sample.

*62*  
89. (previously presented) The method of claim *88* wherein the antibody or fragment thereof is a polyclonal antibody.<sup>61</sup>

*63*  
90. (previously presented) An isolated antibody or fragment thereof obtained from an animal that has been immunized with a protein selected from the group consisting of:

- (a) a protein comprising the amino acid sequence of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit Number 209691 or 209641;
- (b) a protein comprising the amino acid sequence of the mature form of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209691 or 209641;
- (c) a protein comprising the amino acid sequence of the extracellular soluble domain of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209691 or 209641;
- (d) a protein comprising the amino acid sequence of at least 30 contiguous amino acid residues of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209691 or 209641; and

(e) a protein comprising the amino acid sequence of at least 50 contiguous amino acid residues the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209691 or 209641;

wherein said antibody or fragment thereof specifically binds to said amino acid sequence.

67  
91. (previously presented) The antibody or fragment thereof of claim 90 obtained from an animal immunized with protein (a).

68  
92. (previously presented) The antibody or fragment thereof of claim 90 obtained from an animal immunized with protein (b).

69  
93. (previously presented) The antibody or fragment thereof of claim 90 obtained from an animal immunized with protein (c).

70  
94. (previously presented) The antibody or fragment thereof of claim 90 obtained from an animal immunized with protein (d).

71  
95. (previously presented) The antibody or fragment thereof of claim 90 obtained from an animal immunized with protein (e).

72  
96. (previously presented) The antibody or fragment thereof of claim 90, which is a monoclonal antibody.

73  
97. (previously presented) The antibody or fragment thereof of claim 90, which is selected from the group consisting of:

- (a) a chimeric antibody;
- (b) a polyclonal antibody;
- (c) a humanized antibody;
- (d) a single chain antibody; and

(e) a Fab fragment.

- 74  
98. (previously presented) An isolated monoclonal antibody or fragment thereof that specifically binds to a protein selected from the group consisting of:
- (a) a protein consisting of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit Number 209691 or 209641;
  - (b) a protein consisting of the mature form of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209691 or 209641;
  - (c) a protein consisting of the extracellular soluble domain of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209691 or 209641;
  - (d) a protein consisting of a portion of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209691 or 209641, wherein said portion comprises at least 30 contiguous amino acid residues of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209691 or 209641; and
  - (e) a protein consisting of a portion of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209691 or 209641, wherein said portion comprises at least 50 contiguous amino acid residues of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209691 or 209641.

75  
74  
99. (previously presented) The antibody or fragment thereof of claim 98 that specifically binds protein (a).

77  
74  
100. (previously presented) The antibody or fragment thereof of claim 98 that specifically binds protein (b).

88  
74  
101. (previously presented) The antibody or fragment thereof of claim 98 that specifically binds protein (c).

89  
74  
102. (previously presented) The antibody or fragment thereof of claim 98 that specifically binds protein (d).

~~90~~ 103. (previously presented) The antibody or fragment thereof of claim ~~98~~ <sup>74</sup> that specifically binds protein (e).

~~76~~ 104. (previously presented) The antibody or fragment thereof of claim ~~99~~ <sup>75</sup> that specifically binds protein (b).

~~78~~ 105. (previously presented) The antibody or fragment thereof of claim ~~100~~ <sup>77</sup> wherein said protein bound by said antibody or fragment thereof is glycosylated.

~~79~~ 106. (previously presented) The antibody or fragment thereof of claim ~~100~~ <sup>77</sup>, which is a human antibody.

~~80~~ 107. (previously presented) The antibody or fragment thereof of claim ~~100~~ <sup>77</sup>, which is selected from the group consisting of:

- (a) a chimeric antibody;
- (b) a humanized antibody;
- (c) a single chain antibody; and
- (d) a Fab fragment.

~~81~~ 108. (previously presented) The antibody or fragment thereof of claim ~~100~~ <sup>77</sup>, which is labeled.

~~82~~ 109. (previously presented) The antibody or fragment thereof of claim ~~108~~ <sup>81</sup>, wherein the label is selected from the group consisting of:

- (a) an enzyme;
- (b) a fluorescent label;
- (c) a luminescent label;
- (d) a bioluminescent label; and
- (e) a prosthetic group.

<sup>83</sup>  
110. (previously presented) The antibody or fragment thereof of claim 100 wherein said antibody or fragment thereof specifically binds to said protein in a Western blot.

<sup>84</sup>  
111. (previously presented) The antibody or fragment thereof of claim 100 wherein said antibody or fragment thereof specifically binds to said protein in an ELISA.

<sup>85</sup>  
112. (previously presented) An isolated cell that produces the antibody or fragment thereof of claim 100.<sup>77</sup>

<sup>86</sup>  
113. (previously presented) A hybridoma that produces the antibody or fragment thereof of claim 100.<sup>77</sup>

<sup>87</sup>  
114. (currently amended) A method of detecting CRGGCL cytokine receptor common gamma chain like protein in a biological sample comprising:

- (a) contacting the biological sample with the antibody or fragment thereof of claim 100; and
- (b) detecting the CRGGCL cytokine receptor common gamma chain like protein in the biological sample.

<sup>91</sup>  
115. (currently amended) An isolated antibody or fragment thereof that specifically binds a CRGGCL cytokine receptor common gamma chain like protein expressed on the surface of a cell, said cell comprising a polynucleotide encoding amino acids +1 to +371 of SEQ ID NO:2 operably associated with a regulatory sequence that controls the expression of said polynucleotide.

<sup>92</sup>  
116. (previously presented) The antibody or fragment thereof of claim 115,<sup>91</sup> which is a monoclonal antibody.

*33*  
~~117.~~ (previously presented) The antibody or fragment thereof of claim ~~115~~,  
which is a human antibody. *91*

*34*  
~~118.~~ (previously presented) The antibody or fragment thereof of claim ~~115~~,  
which is selected from the group consisting of: *91*

- (a) a chimeric antibody;
- (b) a polyclonal antibody;
- (c) a humanized antibody;
- (d) a single chain antibody; and
- (e) a Fab fragment.

*35*  
~~119.~~ (previously presented) The antibody or fragment thereof of claim ~~115~~,  
wherein said antibody or fragment thereof specifically binds to said protein in a Western  
blot. *91*

*36*  
~~120.~~ (previously presented) The antibody or fragment thereof of claim ~~115~~,  
wherein said antibody or fragment thereof specifically binds to said protein in an ELISA. *91*